IMITREX tablet contraindications: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi- (talk | contribs) |
Gerald Chi- (talk | contribs) |
||
| Line 13: | Line 13: | ||
* History of [[stroke]] or [[transient ischemic attack]] (TIA) or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke [see Warnings and Precautions (5.4)] | * History of [[stroke]] or [[transient ischemic attack]] (TIA) or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke [see Warnings and Precautions (5.4)] | ||
* Peripheral vascular disease [see Warnings and Precautions (5.5)] | * [[Peripheral vascular disease]] [see Warnings and Precautions (5.5)] | ||
* Ischemic bowel disease [see Warnings and Precautions (5.5)] | * [[Ischemic bowel disease]] [see Warnings and Precautions (5.5)] | ||
* Uncontrolled hypertension [see Warnings and Precautions (5.8)] | * Uncontrolled [[hypertension]] [see Warnings and Precautions (5.8)] | ||
* Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5- | * Recent use (i.e., within 24 hours) of [[ergotamine]]-containing medication, [[ergot]]-type medication (such as [[dihydroergotamine]] or [[methysergide]]), or another 5-hydroxytryptamine (5-HT1) agonist [see Drug Interactions (7.1, 7.3)] | ||
* Concurrent administration of a monoamine oxidase (MAO)-A inhibitor or recent (within 2 weeks) use of an MAO-A inhibitor [see Drug Interactions (7.2) and Clinical Pharmacology (12.3)] | * Concurrent administration of a [[monoamine oxidase|monoamine oxidase (MAO)]]-A inhibitor or recent (within 2 weeks) use of an MAO-A inhibitor [see Drug Interactions (7.2) and Clinical Pharmacology (12.3)] | ||
* Hypersensitivity to IMITREX (angioedema and anaphylaxis seen) [see Warnings and Precautions (5.9)] | * [[Hypersensitivity]] to IMITREX ([[angioedema]] and [[anaphylaxis]] seen) [see Warnings and Precautions (5.9)] | ||
* Severe hepatic impairment [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)]<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = IMITREX (SUMATRIPTAN SUCCINATE) TABLET, FILM COATED [GLAXOSMITHKLINE LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=584abe73-8290-4484-ff8e-5890831c095e | publisher = | date = | accessdate = }}</ref> | * Severe hepatic impairment [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)]<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = IMITREX (SUMATRIPTAN SUCCINATE) TABLET, FILM COATED [GLAXOSMITHKLINE LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=584abe73-8290-4484-ff8e-5890831c095e | publisher = | date = | accessdate = }}</ref> | ||
Latest revision as of 22:41, 19 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Contraindications
IMITREX Tablets are contraindicated in patients with:
- Ischemic coronary artery disease (CAD) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including Prinzmetal’s angina [see Warnings and Precautions (5.1)]
- Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see Warnings and Precautions (5.2)]
- History of stroke or transient ischemic attack (TIA) or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke [see Warnings and Precautions (5.4)]
- Peripheral vascular disease [see Warnings and Precautions (5.5)]
- Ischemic bowel disease [see Warnings and Precautions (5.5)]
- Uncontrolled hypertension [see Warnings and Precautions (5.8)]
- Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine (5-HT1) agonist [see Drug Interactions (7.1, 7.3)]
- Concurrent administration of a monoamine oxidase (MAO)-A inhibitor or recent (within 2 weeks) use of an MAO-A inhibitor [see Drug Interactions (7.2) and Clinical Pharmacology (12.3)]
- Hypersensitivity to IMITREX (angioedema and anaphylaxis seen) [see Warnings and Precautions (5.9)]
- Severe hepatic impairment [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)][1]
References
Adapted from the FDA Package Insert.